Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Opioid Use Disorder Topic Center

Featured

News
One Year After ‘X Waiver’ Axing, Few New Patients Prescribed Meds for OUD
05/15/2024
Brionna Mendoza
Though the number of buprenorphine prescribers increased following the elimination of the X waiver in January 2023, the total number of patients using the medication to manage opioid use disorder (OUD) “changed little.”
Though the number of buprenorphine prescribers increased following the elimination of the X waiver in January 2023, the total number of patients using the medication to manage opioid use disorder (OUD) “changed little.”
Though the number of...
05/15/2024
Psych Congress Network
rx summit
News
RX Summit Presenters Embrace Harm Reduction for Recovery-Ready Communities
04/09/2024
Jolynn Tumolo
Harm reduction services for people with SUD demonstrate efficacy, but they continue to encounter social stigma and barriers, according to a poster presentation at the RX and Illicit Drug Summit.
Harm reduction services for people with SUD demonstrate efficacy, but they continue to encounter social stigma and barriers, according to a poster presentation at the RX and Illicit Drug Summit.
Harm reduction services for...
04/09/2024
Psychiatry & Behavioral Health
From Psychiatry & Behavioral Health
Client at Pharmacy
News
Financial, Insurance Barriers May Interfere with Buprenorphine Dispensing at Pharmacy
04/02/2024
Jolynn Tumolo
Financial and insurance restrictions appear to deter some patients from filling buprenorphine prescriptions, according to a poster presented at the RX and Illicit Drug Summit.
Financial and insurance restrictions appear to deter some patients from filling buprenorphine prescriptions, according to a poster presented at the RX and Illicit Drug Summit.
Financial and insurance...
04/02/2024
Psychiatry & Behavioral Health
From Psychiatry & Behavioral Health
News
Vertex Prepares to Submit New Drug Application for Medication to Treat Acute Pain
02/01/2024

Tom Valentino

Tom Valentino
After announcing positive results in its Phase 3 program for its selective NaV1.8 inhibitor that was developed as an alternative to opioids for treating moderate-to-severe acute pain, Vertex Pharmaceuticals plans to submit its NDA application...
After announcing positive results in its Phase 3 program for its selective NaV1.8 inhibitor that was developed as an alternative to opioids for treating moderate-to-severe acute pain, Vertex Pharmaceuticals plans to submit its NDA application...
After announcing positive...
02/01/2024
Addiction Professional
From Addiction Professional
News
Study Finds No Significant Link Between Cannabis Use and Relapse in OUD Patients
01/26/2024

Tom Valentino

Tom Valentino
A recent meta-analysis of 10 longitudinal studies conducted by Yale University researchers found no significant link between cannabis use and relapse on non-medical opioids among patients receiving medication-assisted treatment for opioid use...
A recent meta-analysis of 10 longitudinal studies conducted by Yale University researchers found no significant link between cannabis use and relapse on non-medical opioids among patients receiving medication-assisted treatment for opioid use...
A recent meta-analysis of 10...
01/26/2024
Addiction Professional
From Addiction Professional

Advertisement

News

News
One Year After ‘X Waiver’ Axing, Few New Patients Prescribed Meds for OUD
05/15/2024
Brionna Mendoza
Though the number of buprenorphine prescribers increased following the elimination of the X waiver in January 2023, the total number of patients using the medication to manage opioid use disorder (OUD) “changed little.”
Though the number of buprenorphine prescribers increased following the elimination of the X waiver in January 2023, the total number of patients using the medication to manage opioid use disorder (OUD) “changed little.”
Though the number of...
05/15/2024
Psych Congress Network
rx summit
News
RX Summit Presenters Embrace Harm Reduction for Recovery-Ready Communities
04/09/2024
Jolynn Tumolo
Harm reduction services for people with SUD demonstrate efficacy, but they continue to encounter social stigma and barriers, according to a poster presentation at the RX and Illicit Drug Summit.
Harm reduction services for people with SUD demonstrate efficacy, but they continue to encounter social stigma and barriers, according to a poster presentation at the RX and Illicit Drug Summit.
Harm reduction services for...
04/09/2024
Psychiatry & Behavioral Health
Client at Pharmacy
News
Financial, Insurance Barriers May Interfere with Buprenorphine Dispensing at Pharmacy
04/02/2024
Jolynn Tumolo
Financial and insurance restrictions appear to deter some patients from filling buprenorphine prescriptions, according to a poster presented at the RX and Illicit Drug Summit.
Financial and insurance restrictions appear to deter some patients from filling buprenorphine prescriptions, according to a poster presented at the RX and Illicit Drug Summit.
Financial and insurance...
04/02/2024
Psychiatry & Behavioral Health
News
Vertex Prepares to Submit New Drug Application for Medication to Treat Acute Pain
02/01/2024

Tom Valentino

Tom Valentino
After announcing positive results in its Phase 3 program for its selective NaV1.8 inhibitor that was developed as an alternative to opioids for treating moderate-to-severe acute pain, Vertex Pharmaceuticals plans to submit its NDA application...
After announcing positive results in its Phase 3 program for its selective NaV1.8 inhibitor that was developed as an alternative to opioids for treating moderate-to-severe acute pain, Vertex Pharmaceuticals plans to submit its NDA application...
After announcing positive...
02/01/2024
Addiction Professional
News
Study Finds No Significant Link Between Cannabis Use and Relapse in OUD Patients
01/26/2024

Tom Valentino

Tom Valentino
A recent meta-analysis of 10 longitudinal studies conducted by Yale University researchers found no significant link between cannabis use and relapse on non-medical opioids among patients receiving medication-assisted treatment for opioid use...
A recent meta-analysis of 10 longitudinal studies conducted by Yale University researchers found no significant link between cannabis use and relapse on non-medical opioids among patients receiving medication-assisted treatment for opioid use...
A recent meta-analysis of 10...
01/26/2024
Addiction Professional
A young Black boy sits on the floor of a living room holding a video game controller and concentrated on his game
News
Virtual Gaming May Enhance Working Memory for Youth With ADHD
05/17/2024
Brionna Mendoza
A literature review presented via poster at the 2024 American Psychiatric Association Annual Meeting in New York City suggests that video games may not be all-harm in effect for youth with ADHD.
A literature review presented via poster at the 2024 American Psychiatric Association Annual Meeting in New York City suggests that video games may not be all-harm in effect for youth with ADHD.
A literature review presented...
05/17/2024
Psych Congress Network
News
One Year After ‘X Waiver’ Axing, Few New Patients Prescribed Meds for OUD
05/15/2024
Brionna Mendoza
Though the number of buprenorphine prescribers increased following the elimination of the X waiver in January 2023, the total number of patients using the medication to manage opioid use disorder (OUD) “changed little.”
Though the number of buprenorphine prescribers increased following the elimination of the X waiver in January 2023, the total number of patients using the medication to manage opioid use disorder (OUD) “changed little.”
Though the number of...
05/15/2024
Psych Congress Network
ketamine brain image
News
Study Findings Support Esketamine and Psilocybin as Effective TRD Treatments
05/14/2024
Meagan Thistle
To address the challenges and “inadequate outcomes” with monoamine-based therapies, a Toronto-based research team investigated novel alternatives for TRD.
To address the challenges and “inadequate outcomes” with monoamine-based therapies, a Toronto-based research team investigated novel alternatives for TRD.
To address the challenges and...
05/14/2024
Psych Congress Network
A depressed teen rides the bus and looks at a smartphone in their hand
News
Adolescents May Not Reliably Signal Self-Harm Risk on PHQ in Primary Care Screenings
05/13/2024
Jolynn Tumolo
Teens with depression who were screened in primary care had higher odds of responding “not at all” to a question about thoughts of death or self-harm in the days and weeks before a self-harm event or death by suicide.
Teens with depression who were screened in primary care had higher odds of responding “not at all” to a question about thoughts of death or self-harm in the days and weeks before a self-harm event or death by suicide.
Teens with depression who were...
05/13/2024
Psych Congress Network
TD Has ‘Severe Impact’ on Patients and Caregivers
News
TD Has ‘Severe Impact’ on Patients and Caregivers
05/10/2024
Evi Arthur
Tardive dyskinesia (TD) was found to have a “severe impact” on the lives of both patients and their caregivers across physical, psychological, and social domains. Results from the survey-based study were published in the Journal of Patient...
Tardive dyskinesia (TD) was found to have a “severe impact” on the lives of both patients and their caregivers across physical, psychological, and social domains. Results from the survey-based study were published in the Journal of Patient...
Tardive dyskinesia (TD) was...
05/10/2024
Psych Congress Network
Stimulant Use May Increase Heart Damage Risk in Young Adults With ADHD
News
Stimulant Use May Increase Heart Damage Risk in Young Adults With ADHD
05/07/2024
Evi Arthur
Stimulant use for attention-deficit/hyperactivity disorder (ADHD) could increase risk of heart damage in young adults, according to recent results published in the Journal of the American College of Cardiology. 
Stimulant use for attention-deficit/hyperactivity disorder (ADHD) could increase risk of heart damage in young adults, according to recent results published in the Journal of the American College of Cardiology. 
Stimulant use for...
05/07/2024
Psych Congress Network
woman looking down on phone
News
MDD Prevalence Tripled in Female Huntington Disease Patients
05/07/2024
Jolynn Tumolo
The prevalence of MDD at a major health system was 3 times higher in female patients with Huntington disease (HD) than in male patients, according to a poster presentation APA Annual Meeting.
The prevalence of MDD at a major health system was 3 times higher in female patients with Huntington disease (HD) than in male patients, according to a poster presentation APA Annual Meeting.
The prevalence of MDD at a major...
05/07/2024
Psych Congress Network
brain imaging
News
Overlooked Concussion in Children May Cause Mental Health Comorbidities
05/02/2024
Meagan Thistle
Children who show significant symptoms after head injury are more likely to experience mental and social disturbances and require mental health services, but 23% aren't being evaluated for concussion or brain trauma.
Children who show significant symptoms after head injury are more likely to experience mental and social disturbances and require mental health services, but 23% aren't being evaluated for concussion or brain trauma.
Children who show significant...
05/02/2024
Psych Congress Network
ADHD Medication Use, Particularly Stimulants, Tied to Fewer Hospitalizations
News
ADHD Medication Use, Particularly Stimulants, Tied to Fewer Hospitalizations
05/01/2024
Evi Arthur
In a recent cohort study, use of medication for ADHD, especially lisdexamphetamine and other stimulants, was associated with fewer hospitalizations, and lower suicidal behavior, according to results published in JAMA Network Open. 
In a recent cohort study, use of medication for ADHD, especially lisdexamphetamine and other stimulants, was associated with fewer hospitalizations, and lower suicidal behavior, according to results published in JAMA Network Open. 
In a recent cohort study, use of...
05/01/2024
Psych Congress Network
FDA approval stamp
News
FDA Approves First Prescription Digital Therapeutic for Adjunctive Major Depressive Disorder Treatment
04/30/2024
Meagan Thistle
Rejoyn has been FDA approved as the first prescription digital therapeutic for the treatment of MDD symptoms as an adjunct to clinician-managed outpatient care for adult patients.
Rejoyn has been FDA approved as the first prescription digital therapeutic for the treatment of MDD symptoms as an adjunct to clinician-managed outpatient care for adult patients.
Rejoyn has been FDA approved as...
04/30/2024
Psych Congress Network

Quizzes (coming soon!)

Pencils spell out quiz on their erasers
Quiz
Which tech challenges can telehealth providers expect to encounter most often?
05/14/2024
Hone your telepsychiatry skills with this quiz!
Hone your telepsychiatry skills with this quiz!
Hone your telepsychiatry skills...
05/14/2024
Psych Congress Network
Does in utero stimulant use increase risk of childhood neurodevelopmental disorders?
Quiz
Does in utero stimulant exposure increase risk of childhood neurodevelopmental disorders?
05/12/2024
Test your knowledge!
Test your knowledge!
Test your knowledge!
05/12/2024
Psych Congress Network
Why can bipolar disorder often be misdiagnosed as MDD?
Expert Insights Quiz
Why is bipolar disorder often misdiagnosed as MDD?
05/10/2024
Do you remember this Q&A with Dr Roger McIntyre?
Do you remember this Q&A with Dr Roger McIntyre?
Do you remember this Q&A with Dr...
05/10/2024
Psych Congress Network
Three illustrated faces, one sad, one neutral, one happy.
Quiz
Pediatric ADHD and Schizophrenia Risk
05/01/2024
Test your psychiatry knowledge with this quiz!
Test your psychiatry knowledge with this quiz!
Test your psychiatry knowledge...
05/01/2024
Psych Congress Network
FDA
Quiz
What were the FDA's preliminary findings after investigating GLP-1 RAs?
04/25/2024
Do you remember this FDA update?
Do you remember this FDA update?
Do you remember this FDA update?
04/25/2024
Psych Congress Network
Quiz
For TD, the APA recommends performing an assessment with a structured instrument how often?
04/18/2024
When treating tardive dyskinesia (TD), the American Psychiatric Association (APA) recommends performing an assessment with a structured instrument (e.g., AIMS, DISCUS) how often?
When treating tardive dyskinesia (TD), the American Psychiatric Association (APA) recommends performing an assessment with a structured instrument (e.g., AIMS, DISCUS) how often?
When treating tardive dyskinesia...
04/18/2024
Psych Congress Network
PCN quiz
Quiz
For TD, the APA recommends performing an assessment with a structured instrument how often?
04/18/2024
When treating tardive dyskinesia (TD), the American Psychiatric Association (APA) recommends performing an assessment with a structured instrument (e.g., AIMS, DISCUS) how often?
When treating tardive dyskinesia (TD), the American Psychiatric Association (APA) recommends performing an assessment with a structured instrument (e.g., AIMS, DISCUS) how often?
When treating tardive dyskinesia...
04/18/2024
Psych Congress Network
Women with ADHD are diagnosed how many years after men?
Quiz
Women with ADHD are diagnosed how many years after men?
04/17/2024
Do you remember the details of this study?
Do you remember the details of this study?
Do you remember the details of...
04/17/2024
Psych Congress Network
In an illustrated cartoon style, a man sits on the ground with his head in his hands
Quiz
Global Schizophrenia Care Rates
04/15/2024
Put your knowledge to the test with this quick quiz!
Put your knowledge to the test with this quick quiz!
Put your knowledge to the test...
04/15/2024
Psych Congress Network
Do men or women have an earlier age at onset of OCD?
Quiz
Do men or women have an earlier age at onset of OCD?
03/22/2024
Do a quick refresh on your diagnostic knowledge!
Do a quick refresh on your diagnostic knowledge!
Do a quick refresh on your...
03/22/2024
Psych Congress Network

Advertisement

Advertisement

Sign Up

Psych Congress Network Newsletter

Advertisement

Recent Stories

News
One Year After ‘X Waiver’ Axing, Few New Patients Prescribed Meds for OUD
05/15/2024
Brionna Mendoza
Though the number of buprenorphine prescribers increased following the elimination of the X waiver in January 2023, the total number of patients using the medication to manage opioid use disorder (OUD) “changed little.”
Though the number of buprenorphine prescribers increased following the elimination of the X waiver in January 2023, the total number of patients using the medication to manage opioid use disorder (OUD) “changed little.”
Though the number of...
05/15/2024
Psych Congress Network
rx summit
News
RX Summit Presenters Embrace Harm Reduction for Recovery-Ready Communities
04/09/2024
Jolynn Tumolo
Harm reduction services for people with SUD demonstrate efficacy, but they continue to encounter social stigma and barriers, according to a poster presentation at the RX and Illicit Drug Summit.
Harm reduction services for people with SUD demonstrate efficacy, but they continue to encounter social stigma and barriers, according to a poster presentation at the RX and Illicit Drug Summit.
Harm reduction services for...
04/09/2024
Psychiatry & Behavioral Health
Client at Pharmacy
News
Financial, Insurance Barriers May Interfere with Buprenorphine Dispensing at Pharmacy
04/02/2024
Jolynn Tumolo
Financial and insurance restrictions appear to deter some patients from filling buprenorphine prescriptions, according to a poster presented at the RX and Illicit Drug Summit.
Financial and insurance restrictions appear to deter some patients from filling buprenorphine prescriptions, according to a poster presented at the RX and Illicit Drug Summit.
Financial and insurance...
04/02/2024
Psychiatry & Behavioral Health
News
Vertex Prepares to Submit New Drug Application for Medication to Treat Acute Pain
02/01/2024

Tom Valentino

Tom Valentino
After announcing positive results in its Phase 3 program for its selective NaV1.8 inhibitor that was developed as an alternative to opioids for treating moderate-to-severe acute pain, Vertex Pharmaceuticals plans to submit its NDA application...
After announcing positive results in its Phase 3 program for its selective NaV1.8 inhibitor that was developed as an alternative to opioids for treating moderate-to-severe acute pain, Vertex Pharmaceuticals plans to submit its NDA application...
After announcing positive...
02/01/2024
Addiction Professional
News
Study Finds No Significant Link Between Cannabis Use and Relapse in OUD Patients
01/26/2024

Tom Valentino

Tom Valentino
A recent meta-analysis of 10 longitudinal studies conducted by Yale University researchers found no significant link between cannabis use and relapse on non-medical opioids among patients receiving medication-assisted treatment for opioid use...
A recent meta-analysis of 10 longitudinal studies conducted by Yale University researchers found no significant link between cannabis use and relapse on non-medical opioids among patients receiving medication-assisted treatment for opioid use...
A recent meta-analysis of 10...
01/26/2024
Addiction Professional

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement